Evidence map›Paper›PMID 36648230›Full record

ArticleAntimicrobial agents and chemotherapy2023

Structural and Biochemical Features of OXA-517: a Carbapenem and Expanded-Spectrum Cephalosporin Hydrolyzing OXA-48 Variant.

Laura Dabos, Joanna E Raczynska, Pierre Bogaerts, Agustin Zavala, Delphine Girlich, Remy A Bonnin, Laurent Dortet, Aurélie Peyrat, Pascal Retailleau, Bogdan I Iorga and 3 more

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Characterization of GUA-1, a chromosomally encoded ESBL fromAntimicrobial agents and chemotherapy · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Laura DabosTeam "Resist" UMR1184, INSERM, CEA, University Paris-Saclay, LabEx LERMIT, Faculty of Medicine, Le Kremlin-Bicêtre, France.
Joanna E RaczynskaCenter for Biocrystallographic Research, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Pierre BogaertsLaboratory of Clinical Microbiology, National Reference Center for Monitoring Antimicrobial Resistance in Gram-Negative Bacteria, CHU UCL Namur, Yvoir, Belgium.
Agustin ZavalaUniversité Paris-Saclay, CNRS UPR 2301, Institut de Chimie des Substances Naturelles, Labex LERMIT, Gif-sur-Yvette, France.
Delphine GirlichTeam "Resist" UMR1184, INSERM, CEA, University Paris-Saclay, LabEx LERMIT, Faculty of Medicine, Le Kremlin-Bicêtre, France.
Remy A BonninTeam "Resist" UMR1184, INSERM, CEA, University Paris-Saclay, LabEx LERMIT, Faculty of Medicine, Le Kremlin-Bicêtre, France.
Laurent DortetTeam "Resist" UMR1184, INSERM, CEA, University Paris-Saclay, LabEx LERMIT, Faculty of Medicine, Le Kremlin-Bicêtre, France.ORCID 0000-0001-6596-7384
Aurélie PeyratTeam "Resist" UMR1184, INSERM, CEA, University Paris-Saclay, LabEx LERMIT, Faculty of Medicine, Le Kremlin-Bicêtre, France.
Pascal RetailleauUniversité Paris-Saclay, CNRS UPR 2301, Institut de Chimie des Substances Naturelles, Labex LERMIT, Gif-sur-Yvette, France.
Bogdan I IorgaUniversité Paris-Saclay, CNRS UPR 2301, Institut de Chimie des Substances Naturelles, Labex LERMIT, Gif-sur-Yvette, France.ORCID 0000-0003-0392-1350
Mariusz JaskólskiCenter for Biocrystallographic Research, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Youri GlupczynskiLaboratory of Clinical Microbiology, National Reference Center for Monitoring Antimicrobial Resistance in Gram-Negative Bacteria, CHU UCL Namur, Yvoir, Belgium.
Thierry NaasTeam "Resist" UMR1184, INSERM, CEA, University Paris-Saclay, LabEx LERMIT, Faculty of Medicine, Le Kremlin-Bicêtre, France.ORCID 0000-0001-9937-9572
Inserm · FRCentre National de la Recherche Scientifique · FRCHU Dinant Godinne UCL Namur · BEInstitute of Bioorganic Chemistry, Polish Academy of Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

OXA-48-producing Enterobacterales have now widely disseminated throughout the world. Several variants have now been reported, differing by just a few amino-acid substitutions or deletions, mostly in the region of the loop β5-β6. As OXA-48 hydrolyzes carbapenems but lacks significant expanded-spectrum cephalosporin (ESC) hydrolytic activity, ESCs were suggested as a therapeutic option. Here, we have characterized OXA-517, a natural variant of OXA-48- with an Arg214Lys substitution and a deletion of Ile215 and Glu216 in the β5-β6 loop, capable of hydrolyzing at the same time ESC and carbapenems. MICs values of E. coli expressing

Indexed as

CarbapenemsCephalosporinsAnti-Bacterial Agentsbeta-LactamasesCeftazidimeEscherichia coliMicrobial Sensitivity TestsMonobactamsAnti-Bacterial Agentsbeta-LactamasesCarbapenemsCeftazidimeCephalosporinsMonobactamsantibiotic resistancecarbapenemcephalosporinextended-spectrum β-lactamasehydrolysisoxacillinase

Identifiers

PMID36648230
PMCPMC9933634
OpenAlexW4316928391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.